HARMONY BIOSCIENCES (HRMY) Q3 2025 SUMMARY
Financial Performance & Capital Structure Nine-month Net Product Revenue grew 21.7% to \(624.7M, driven by price increases and unit growth, with Net Income reaching \)136.2M (\(2.32 Diluted EPS). Total liquidity is robust, with Cash and Investments totaling \)778.4M, supporting management guidance for more than 12 months of operations. Total Assets reached \(1.208B, and Total Stockholders Equity improved significantly to \)835.1M, marked by Retained Earnings reversing from a deficit to \(138.4M. Total net debt decreased to \)168.5M. The Effective Tax Rat
...